CNTA
Research Snapshot
Static fundamentals, valuation context, and investor signals for CENTESSA PHARMACEUTICALS PLC (CNTA).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-31.0%
ROIC, -1294.6% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.2x
Debt/equity, 8.6x current ratio
Superinvestors
1
Top: Lee Ainslie (0.9%)
Strengths to research
- Debt/equity looks manageable at 0.2x.
Watchouts
- Free cash flow margin is negative at -1294.6%.
- Valuation multiples are limited or unavailable.
Annual data: 7 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for CNTA.
Grade F
1
/ 100
Financial Charts
No financial data available for CNTA (annual).
1 superinvestors own CNTA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 1,854,488 | $74M | 0.86% | 0.0% |